CULVER CITY, Calif — NantHealth, Inc., (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, announced today that Phoenix Children’s Hospital, one of the leading children’s hospitals nationwide and founding member of the Cancer Breakthroughs 2020 Pediatrics Consortium, has entered into a commercial licensing agreement for NantHealth’s suite of precision medicine and healthcare IT solutions. These include GPS Cancer™, the leading molecular test for personalized cancer therapy, the eviti^® oncology decision support platform, named #1 Clinical Decision Support solution for 2016 by Black Book Market Research, and NantHealth’s patient engagement, care coordination, and analytics solutions built on NantOS™, the industry’s leading cloud-based, healthcare platform.

Adoption of GPS Cancer™ for pediatric patients and employees

Under the terms of the agreement, Phoenix Children’s Hospital will leverage the power of GPS Cancer, a molecular test integrating whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics in two ways. First, its network of oncologists will be able to order GPS Cancer, enabling them to gain critical insights to inform personalized treatment strategies including guided chemotherapies, FDA-approved targeted drugs, and active clinical trials for their pediatric cancer patients. Second, Phoenix Children’s Hospital will cover GPS Cancer for its employees and their families, making it one of the nation’s first self-insured employers to cover proteogenomic sequencing for a variety of cancers.

Adoption of healthcare IT solutions for precision cancer care

In addition, by combining GPS Cancer with NantHealth’s software portfolio, Phoenix Children’s Hospital will be able to more easily manage and coordinate care for its patient population, thereby helping to improve engagement, reduce costs, and deliver on value-based outcomes. NantHealth’s solutions to be deployed at Phoenix Children’s Hospital include those for:

• Oncology decision support: Through the eviti decision support platform, oncologists will have access to evidence-based regimens, condition-specific clinical trials options, and capabilities to streamline preauthorization in advance of cancer treatments. With eviti, Phoenix Children’s joins over 75 percent of U.S. oncology practices who have adopted eviti platform to make better clinical decisions earlier in the treatment process.
• Patient engagement: With the NantHealth Patient Portal, patients will be able to access test results, expedite appointment scheduling, and securely communicate with Phoenix Children’s Hospital doctors through a web-based interface, enabling them to be more fully engaged with their care teams. In addition, the Health Heritage web application will allow patients to easily collect and share their family health histories with families and providers to improve care decision-making.
• Care coordination: The NantHealth Provider Portal will equip Phoenix Children’s Hospital providers with unified access to a 360° view of the patient across disparate locations and episodes of care. Through the NantHealth Referral Management application, doctors and administrators will be able to transform a tedious referral processes into a streamlined workflow connecting multiple sources of information and facilities into a single referral resource. Finally, the NantHealth Care Coordination application will help enable seamless collaboration across care settings, including post-discharge care coordination, urgent care triage, wellness programs, and transition of care.
• Analytics and Clinical Learning: NantHealth’s analytics and clinical learning solutions, including the NantHealth Outcomes Analytics and NantHealth Value Monitor applications, will enable Phoenix Children’s Hospital to measure and monitor key provider performance metrics to drive continuous improvement initiatives through rich dashboards.

“NantHealth’s GPS Cancer test and expansive healthcare IT portfolio provides us with the rich set of clinical and technical solutions to deliver the most advanced care possible for our patients,” said Robert L. Meyer, President and CEO, Phoenix Children’s Hospital. “With GPS Cancer, our network of oncologists will be able to gain insight into the most appropriate, personalized cancer therapies before treatment begins, while NantHealth’s oncology decision support, patient engagement, and care coordination solutions will help our care teams become more efficient—in service of our patients—as we continue to move into a value-based world.”

Mr. Meyer continued, “In addition, our organization’s commitment to utilizing the GPS Cancer test for our employees, and their loved ones who may be facing cancer diagnoses, is important to us as we work to discover new potential therapies and clinical trials for cancer patients in our community.”

“We are excited about this ground-breaking partnership with Phoenix Children’s Hospital, and look forward to helping their oncologists make better, more informed care decisions,” said Patrick Soon-Shiong, MD, CEO of NantHealth. “The fight against cancer and other life-threatening diseases needs to be a collaborative effort that deeply integrates all aspects of our healthcare ecosystem. By combining GPS Cancer with best-in-class healthcare IT, we stand a better chance of understanding a patient’s cancer before therapy begins, while ensuring providers have all the tools they need to effectively manage their patient populations and coordinate care across the continuum. Combined, these capabilities deliver on NantHealth’s 10-year vision of integrating our complex healthcare ecosystem as a real-time, adaptive learning system, and I am excited about the leadership that Phoenix Children’s Hospital has taken to achieve this critical mission.”

Tweet this: “NantHealth’s GPS Cancer test and expansive healthcare IT portfolio provides us with the rich set of clinical and technical solutions to deliver the most advanced care possible for our patients”

Cautionary Note Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the capabilities and anticipated utility of our GPS Cancer, including predicting patient response and resistance to therapeutics, enabling diagnoses by physicians and accelerating efforts to bring novel combinations of therapeutic agents to cancer patients, as well as our contribution to the Cancer 2020 initiative. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results. Factors that may cause future results to differ materially from management’s current expectations include, among other things, that GPS Cancer may not perform as anticipated, that sufficient physicians may not adopt GPS Cancer to assist their diagnoses or that healthcare payers may not provide reimbursement for GPS Cancer as expected. Our business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of our products; our ability to successfully launch new products and applications; competition; our sales, marketing and distribution capabilities; our planned sales, marketing, and research and development activities; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting our business and operating results can be found in our existing and future filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements except as may be required by law.

About NantHealth, Inc.
NantHealth, Inc. a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth‘s unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time. For more information please visit www.nanthealth.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

About Phoenix Children’s Hospital
Phoenix Children’s Hospital, ranked in U.S. News & World Report’s Best Children’s Hospitals, is Arizona’s only licensed children’s hospital, providing world-class inpatient, outpatient, trauma, emergency and urgent care to children and families in Arizona and throughout the Southwest. As one of the largest children’s hospitals in the country, Phoenix Children’s provides care across more than 75 pediatric specialties. The Hospital is poised for continued growth in quality patient care, research and medical education. For more information about the Hospital, visit www.phoenixchildrens.org.